Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Olsztyn – page 6

316 clinical trials in Olsztyn, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Olsztyn at a glance
316
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

316 trials in Olsztyn

Open in trial search

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study comparing high-dose and low-dose aspirin with prasugrel and aspirin combination in patients after coronary artery bypass grafting surgery

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Agencja Badań Medycznych

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Olsztyn

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on acute myeloid leukemia treatments and innovative therapies for various types of lung cancer. Studies include evaluation of new drug combinations and treatment approaches for colorectal cancer and lymphoma.

  • Advanced treatment combinations for leukemia
  • Targeted therapies for NSCLC
  • Novel approaches in lymphoma treatment

Research emphasizes personalized medicine approaches and improving patient outcomes in advanced stages of disease.

02 Dermatology Studies

Innovative research into plaque psoriasis and psoriatic arthritis treatments, including new biological therapies and novel drug combinations. Studies also examine treatments for rare conditions like pyoderma gangrenosum.

  • Biological therapy assessment
  • Chronic skin condition management
  • Combined treatment approaches

Focus on developing more effective treatments for moderate to severe skin conditions.

03 Cardiovascular Research

Studies examining new approaches to heart failure prevention and treatment, including investigations of novel drug combinations. Research focuses on reducing cardiovascular events and improving outcomes in high-risk patients.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Therapeutic combinations

Emphasis on preventive measures and innovative treatment strategies for cardiac conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.